Lowell Anthony MD Of Markey Cancer Center Discusses Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It.
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
